While I agree with the strong bull case for SNTS. I don't agree that Nichols is one of the best in biotech. He's been wrong many times and recommended buys when companies were low on cash and had ATMs on file ready to be cashed in.
I think he's a little lazy on his homework sometimes. Granted, he holds stocks for very long periods of time compared to most of the bio players. So for his long term plays he's pretty decent.